Author

B. Selisko

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Assay:structural biology· 1

Frequent Co-Authors

B. Canard· 3 shared A. Shannon· 2 shared C. Eydoux· 2 shared E. Decroly· 2 shared F. Ferron· 2 shared J.-C. Guillemot· 2 shared V. Fattorini· 2 shared A. K. N. Chan· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

B. Canard

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir

H. S. Lo, K. P. Y. Hui, H.-M. Lai, K. S. Khan, S. Kaur, J. Huang, Z. Li, A. K. N. Chan, H. H.-Y. Cheung, K. C. Ng, J. C. W. Ho, Y. W. Chen, B. Ma, P. M.-H. Cheung, D. Shin, , W.-L. Ng

The paper identifies simeprevir as a potent inhibitor of SARS-CoV-2 replication that synergizes with remdesivir in vitro.

ACS Central Science · Apr 15, 2021Peer-reviewedMicrobiology

Protein-primed RNA synthesis in SARS-CoVs and structural basis for inhibition by AT-527

A. Shannon, V. Fattorini, B. Sama, B. Selisko, M. Feracci, C. Falcou, P. Gauffre, P. El Kazzi, E. Decroly, N. Rabah, K. Toulon, C. Eydoux, J.-C. Guillemot, M. Noel, F. Debart, , B. Canard

This paper identifies a protein-priming mechanism for SARS-CoV RNA synthesis and shows that AT-527 inhibits this process by targeting both NiRAN and RdRp domains.

bioRxiv · Mar 23, 2021Biochemistry

Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase

A. Shannon, B. Selisko, T.-T.-N. Le, J. Huchting, F. Touret, G. Piorkowski, V. Fattorini, F. Ferron, E. Decroly, C. Meier, B. Coutard, O. Peersen, B. Canard

This study shows Favipiravir inhibits SARS-CoV-2 by targeting its RNA polymerase through chain termination, slowed synthesis, and mutagenesis.

bioRxiv · May 15, 2020 · PreprintBiochemistry